Tables and figures

Table I Reliability - Internal consistency: Scores obtained in the FPFQ by sample N° 1 women in the test-retest; intraclass correlation coefficient (ICC) and its confidence interval 95% (95% CI ICC); Cronbach alpha coefficient calculated on the data collected during the first assessment.

N	Mean Test	Mean reTest	Mean difference	ICC	95% CI ICC	α-Cronbach
51	6.2±5.2	5.6±5.2	0.6±3.7	0.7	[0.6 – 0.8]	0.9
51	1.7±1.7	1.4±1.5	0.2±1.2	0.7	[0.6 - 0.8]	0.9
51	1.4±1.2	1.2±1.0	0.2±0.7	0.8	[0.7 - 0.9]	0.8
51	0.8±2.2	0.9±2.0	-0.0±1.6	0.7	[0.5 - 0.8]	0.9
34	2.6±1.7	2.6±2.1	-0.2±1.4	0.7	[0.6 - 0.9]	0.8
	51 51 51 51	51 6.2±5.2 51 1.7±1.7 51 1.4±1.2 51 0.8±2.2	51 6.2±5.2 5.6±5.2 51 1.7±1.7 1.4±1.5 51 1.4±1.2 1.2±1.0 51 0.8±2.2 0.9±2.0	51 6.2±5.2 5.6±5.2 0.6±3.7 51 1.7±1.7 1.4±1.5 0.2±1.2 51 1.4±1.2 1.2±1.0 0.2±0.7 51 0.8±2.2 0.9±2.0 -0.0±1.6	51 6.2±5.2 5.6±5.2 0.6±3.7 0.7 51 1.7±1.7 1.4±1.5 0.2±1.2 0.7 51 1.4±1.2 1.2±1.0 0.2±0.7 0.8 51 0.8±2.2 0.9±2.0 -0.0±1.6 0.7	51 6.2±5.2 5.6±5.2 0.6±3.7 0.7 [0.6 - 0.8] 51 1.7±1.7 1.4±1.5 0.2±1.2 0.7 [0.6 - 0.8] 51 1.4±1.2 1.2±1.0 0.2±0.7 0.8 [0.7 - 0.9] 51 0.8±2.2 0.9±2.0 -0.0±1.6 0.7 [0.5 - 0.8]

Table II Internal consistency: Scores obtained in the FPFQ by patients in the 3PN clinical trial and Cronbach alpha coefficients calculated at baseline (n = 272*).

	N	Mean	α-Cronbach
Total Score /40	254	5.8±3.5	0.8
Bladder Score /10	267	1.6±1.3	0.8
Bowel Score /10	267	1.5±1.2	0.7
POP Score /10	267	0.4±1.1	0.7
Sex Score /10**	232	2.8±2.0	0.8

<u>Table III Construct Validity: Correlations between FPFQ scores on inclusion from patients enrolled in the 3PN</u> study at Nîmes CHU (n = 71); Spearman correlation coefficient.

	FPFQ	р
	Bladder Score	
ICIQ-UISF	0.6	<0.0001
Contilife	-0.6	<0.0001
UDI-6	0.7	<0.0001
UIQ-7	0.6	<0.0001
	Bowel Score	
CRADI-8	0.8	<0.0001
CRAIQ-7	0.4	<0.001
	Pelvic Organ Prolapse (POP) Score	
POPDI-6	0.4	<0.01
POPIQ-7	0.1	0.3916
	Total Score	
	(sex score excluded)	
PFDI-20	0.8	<.0001
PFIQ-7	0.6	<.0001




Figure 1: Representation of the difference in total score of the test-retest based on mean score, as calculated by the Bland-Altman method. Sample No. 1 (n = 51)




Figure 2: Evolution of scores and sub-scores obtained in the FPFQ, the ICIQ-UI-SF, Contilife, the PFDI-20 and PFIQ-7 during longitudinal monitoring of 3PN patients recruited at Nîmes CHU (n=71).